MPLX LP vs Oruka Therapeutics Inc. Common Stock — how do they compare? MPLX LP trades at $57.5 (market cap $57.70B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: MPLX LP is far larger — about 11.1× Oruka Therapeutics Inc. Common Stock's market cap, and MPLX LP pays a 7.57% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| MPLX | ORKA | |
|---|---|---|
Market Cap | $57.70B | $5.18B |
Volume | 561,167 | 490,798 |
Sector | Energy | Health |
52-Week High | $60.51 | $113.08 |
52-Week Low | $48.53 | $26.19 |
Enterprise Value | $82.80B | $4.31B |
Dividend Yield | 7.57% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.91, up 0.14% with a bearish technical signal despite strong fundamentals. The company reported $11.47B revenue and $4.91B net income for 2025, with robust profitability margins (40.45% net margin, 33.95% ROE). Recent earnings show mixed results with Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 12% upside potential.
The investment case balances strong cash flow generation and dividend yield against energy market volatility risks. MPLX's fee-based midstream model provides revenue stability, but recent technical weakness and earnings misses warrant caution. The stock offers value with a 12.24 P/E ratio and dividend income potential, though investors should monitor Q3 2026 earnings due November 3rd for confirmation of business momentum.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →